Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry

This study shows that treatment with dupilumab in daily practice shows a rapid improvement in clinical outcomes measures, and effectiveness sustains or further improves during long-term (52-weeks) treatment.

Source: Journal of the American Academy of Dermatology - September 14, 2020 Category: Dermatology Authors: Lieneke FM. Ari ëns, Jorien van der Schaft, Lotte S. Spekhorst, Daphne S. Bakker, Geertruida L.E. Romeijn, Tessa A. Kouwenhoven, Marijke Kamsteeg, Angelique N. Voorberg, Albert J. Oosting, Ilona de Ridder, Annemieke Sloeserwij, Inge Haeck, Judith L. Thij Source Type: research